# Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

> **NCT06196658** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Zhang Xiaofeng,MD** · enrollment: 6 (estimated)

## Conditions studied

- Pancreatic Cancer
- Advanced Biliary Cancer

## Interventions

- **DRUG:** anti-EX02 CAR T cells

## Key facts

- **NCT ID:** NCT06196658
- **Lead sponsor:** Zhang Xiaofeng,MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2024-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06196658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06196658, "Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06196658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*